| Marginal Zone Lymphoma studied in …STUDIED_INderived200 of 407show all (up to 200) |
|---|
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296070Phase 2 · recruiting Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326308recruiting Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680052Phase 3 · active not recruiting A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792502Phase 2 · recruiting Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07777120active not recruiting Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980116Phase 1 · recruiting Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07759661not yet recruiting Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340737Phase 1 · recruiting AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792825Phase 2 · recruiting HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07744750Phase 2 · not yet recruiting Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708897Phase 1 · recruiting A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07424833Phase 1 · recruiting A Study of APG-3288 in Relapsed/Refractory Blood Cancers · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459608Phase 2 · not yet recruiting Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04333524active not recruiting FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07121946Phase 1 · recruiting This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04212013Phase 3 · active not recruiting A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07713459Phase 2 · not yet recruiting A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711327not yet recruiting Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02494700Phase 2 · active not recruiting Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705308Phase 2 · not yet recruiting A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828589Phase 1 · terminated A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043011recruiting Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06300528Phase 2 · active not recruiting Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04416451Phase 2 · active not recruiting A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805605Phase 2 · recruiting Allo HSCT Using RIC and PTCy for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05131022Phase 1 · recruiting A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339922Phase 2 · active not recruiting Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860880NA · recruiting Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277729Phase 1/Phase 2 · active not recruiting A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700149recruiting Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07376330not yet recruiting Molecular and Cellular Characterization of MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07592481NA · not yet recruiting Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06636175early Phase 1 · recruiting 64Cu-LLP2A for Imaging Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07654465Phase 2 · not yet recruiting Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006117Phase 3 · recruiting Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03162536Phase 1/Phase 2 · active not recruiting A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06224309completed Preliminary Assessment of [18F]BL40 in PET/CT Scans · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195633Phase 2 · recruiting Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609355NA · not yet recruiting AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609446not yet recruiting Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01962636NA · terminated Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01955499Phase 1 · active not recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02362035Phase 1/Phase 2 · completed ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259070Phase 1/Phase 2 · recruiting Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554898Phase 2 · recruiting Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03322865Phase 2 · active not recruiting Obinutuzumab in Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03474744Phase 2 · active not recruiting Copanlisib and Rituximab in Marginal Zone Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03035331Phase 1/Phase 2 · completed Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06125028Phase 3 · terminated [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03479268Phase 1 · active not recruiting Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02433795Phase 2 · completed Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03680586early Phase 1 · active not recruiting Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04433156Phase 2 · completed VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04911478active not recruiting Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03697512Phase 2 · active not recruiting MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04488354Phase 1 · completed Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04646395Phase 2 · active not recruiting Study of Acalabrutinib and Tafasitamab in MZL Patients · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07480863Phase 2 · active not recruiting Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492407not yet recruiting CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06793189Phase 2 · recruiting MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04830137Phase 1 · recruiting A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02952508Phase 2 · active not recruiting Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547115Phase 1 · terminated A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06510309Phase 2 · recruiting Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07448324Phase 2 · recruiting Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441993Phase 2 · recruiting Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03919175Phase 2 · terminated Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04268277Phase 2 · terminated Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151730recruiting Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504940Phase 2 · recruiting Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04186520Phase 1/Phase 2 · recruiting CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04282018Phase 1/Phase 2 · completed Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029217Phase 3 · recruiting A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04775745Phase 1 · recruiting Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191887Phase 1 · recruiting B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04669171Phase 1/Phase 2 · recruiting A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116437Phase 2 · completed Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07372365Phase 2 · recruiting Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740529Phase 1/Phase 2 · completed A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665530Phase 1 · completed A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07355699Phase 4 · recruiting Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223765Phase 1 · recruiting Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01808599Phase 2 · active not recruiting Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03105336Phase 2 · completed A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07299331NA · not yet recruiting Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05602363Phase 1 · recruiting AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390956Phase 2 · recruiting Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07247383Phase 2 · active not recruiting Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07173790enrolling by invitation Watch and Wait or Worry and Wait in Indolent Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449885recruiting A Cohort Study in Newly Diagnosed MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07233720recruiting Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05643742Phase 1/Phase 2 · recruiting A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498612Phase 2 · terminated Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06569680Phase 2 · recruiting Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03452774recruiting SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796998Phase 2 · recruiting Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07208981Phase 2 · recruiting Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03147885Phase 1/Phase 2 · active not recruiting Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04447716Phase 1 · active not recruiting An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04018248Phase 1 · completed BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07144657Phase 2 · not yet recruiting Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02722668Phase 2 · completed UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133221Phase 2 · completed 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995669Phase 1/Phase 2 · completed Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04735471Phase 1 · terminated A Phase 1 Study of ADI-001 in B Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06700798Phase 2 · recruiting Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024147Phase 1 · not yet recruiting JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07022223Phase 2 · recruiting Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07008053Phase 2 · not yet recruiting BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04189952Phase 2 · terminated Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03432741Phase 1 · terminated Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03583424Phase 1/Phase 2 · completed Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578600Phase 1 · completed CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04849351Phase 2 · completed Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719888Phase 2 · completed Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04072458Phase 1 · active not recruiting A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088878Phase 1/Phase 2 · completed A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06823960recruiting Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04599634Phase 1 · completed Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06806488recruiting Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06782854completed Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281809Phase 2 · recruiting Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768505Phase 2 · terminated Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410901Phase 1 · completed TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06534463recruiting Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745832Phase 3 · terminated Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03520920Phase 2 · completed BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03846427Phase 2 · completed Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04358458Phase 1/Phase 2 · terminated First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927964Phase 1/Phase 2 · completed TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659044Phase 2 · terminated Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03078855Phase 3 · completed A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04097067NA · unknown ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00877214Phase 3 · unknown Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00991211Phase 3 · completed Bendamustine Plus Rituximab Versus CHOP Plus Rituximab · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06566807Phase 2 · recruiting Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450069Phase 1 · completed CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04806035Phase 1 · terminated Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06478472NA · recruiting Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04082936Phase 1/Phase 2 · terminated A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06513234Phase 2 · recruiting Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05720052Phase 1/Phase 2 · terminated A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454968Phase 2 · recruiting Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04279405Phase 1 · completed A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06424379unknown BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04995536Phase 1 · withdrawn CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03797456Phase 2 · completed A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01588015Phase 1 · completed Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03329950Phase 1 · completed A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03010982Phase 1 · completed Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04508647Phase 2 · completed Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06228963Phase 2 · recruiting Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858568completed Immune Responses to COVID-19 Vaccination in Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05107856Phase 1 · terminated PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped CURATED_BROADER · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833180Phase 1 · completed A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |